drugset / Trial / NCT02193815

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

NCT02193815

Phase 1 Completed 15 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.

Timeline

Start
2014-09
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcipotriol Small molecule 0.01 mg Topical
Subject PF06263276 Small molecule 8 mg Topical
Subject Tofacitinib Small molecule 4 mg Topical

Indications